7 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 33242536 | Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. | 2021 Feb | 1 |
2 | 34082024 | ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. | 2021 Sep 28 | 2 |
3 | 34262869 | Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. | 2021 | 1 |
4 | 32753881 | Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report. | 2020 | 3 |
5 | 33336070 | A review of current progress in triple-negative breast cancer therapy. | 2020 | 1 |
6 | 29680362 | Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. | 2018 Jun | 1 |
7 | 28471727 | Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. | 2017 Jul 1 | 1 |